Assess Incidence and Prevalence of Brain Metastasis and Its impact on Clinical Outcomes among Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-small Cell Lung Cancer Patients Receiving ALK Inhibitors as First-Line Treatment in the United States (ALK+ mNSCLC)

Study identification

• EU PAS number:
  EUPAS1000000370
• Study ID:
  1000000370
• Official title and acronym:
  Assess Incidence and Prevalence of Brain Metastasis and Its impact on Clinical Outcomes among Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-small Cell Lung Cancer Patients Receiving ALK Inhibitors as First-Line Treatment in the United States (ALK+ mNSCLC)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Ongoing

Research institutions and networks

Institutions

Pfizer

Analysis Group, Inc.

Study timelines

Date when funding contract was signed

Planned: 15/08/2024

Actual: 15/08/2024

Study start date

Planned: 02/12/2024

Actual: 10/12/2024

Date of final study report

Planned: 31/03/2025

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable